Form 4: Vistagen Therapeutics Executive Acquires 170,000 Stock Options
SEC Form 4 Filing
Reid G. Adler, a Vistagen Therapeutics officer, reported the acquisition of 170,000 stock options on June 24, 2024.
Summary
- On June 24, 2024, Reid G. Adler, CHF CORP DEVEL OFF, GEN COUNS of Vistagen Therapeutics, Inc., acquired 170,000 stock options.
- The options have an exercise price of $3.23.
- These options will vest in equal monthly installments over a three-year period, starting on June 24, 2024, and will be fully vested by June 24, 2027.
- The options expire on June 24, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing and does not inherently convey positive or negative sentiment. It simply reports a transaction.
Positives
- The acquisition of stock options by an executive could signal confidence in the company's future performance.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the equity-based compensation of company executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- The vesting schedule of three years is also typical for such grants.
- Comparing the size of the grant to similar companies and executive roles would provide further context.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 06/24/2024 | Date of earliest transaction (grant date of stock options) and Vesting Start Date. |
| 06/24/2034 | Expiration date of the stock options. |
| 06/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.